Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group. - Wikidata - awgldk - TriplyDB

Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group.

Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group.

http://www.wikidata.org/entity/Q27851459

about

Low dose cytarabine monotherapy for acute myeloid leukaemia Hypomethylating agents for adult patients with acute myeloid leukaemia Interleukin-2 as maintenance therapy for children and adults with acute myeloid leukaemia in first complete remission Interleukin-2 as maintenance therapy for children and adults with acute myeloid leukaemia in first complete remission Hypomethylating agents for adult patients with acute myeloid leukaemia Low dose cytarabine monotherapy for acute myeloid leukaemia Histone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agents Defining and Treating Older Adults with Acute Myeloid Leukemia Who Are Ineligible for Intensive Therapies CIViC database A pyrrolo-pyrimidine derivative targets human primary AML stem cells in vivo Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study.Acute myeloid leukemia in the elderly is characterized by a distinct genetic and epigenetic landscape.Interpreting outcome data in hematological malignancies: a paradigm for clinical studies Treatment of therapy-related myeloid neoplasms with high-dose cytarabine/mitoxantrone followed by hematopoietic stem cell transplant.Fractionated gemtuzumab ozogamicin and standard dose cytarabine produced prolonged second remissions in patients over the age of 55 years with acute myeloid leukemia in late first relapse.Efficacy and tolerability of treatment with azacitidine for 5 days in elderly patients with acute myeloid leukemia.Probing the action of a novel anti-leukaemic drug therapy at the single cell level using modern vibrational spectroscopy techniques.Hematopoietic stem cell transplantation rates and long-term survival in acute myeloid and lymphoblastic leukemia: real-world population-based data from the Swedish Acute Leukemia Registry 1997-2006.Challenges in treating older patients with acute myeloid leukemia.Early allo-SCT for AML with a complex aberrant karyotype--results from a prospective pilot study.Adult Acute Myeloid Leukemia Long-term Survivors.Diversity of the juxtamembrane and TKD1 mutations (exons 13-15) in the FLT3 gene with regards to mutant load, sequence, length, localization, and correlation with biological data.The NPM1 mutation type has no impact on survival in cytogenetically normal AML.High-dose cytarabine in acute myeloid leukemia treatment: a systematic review and meta-analysis.The European LeukemiaNet: achievements and perspectives.Feasibility of azacitidine added to standard chemotherapy in older patients with acute myeloid leukemia--a randomised SAL pilot study.Expression and prognostic impact of lncRNAs in acute myeloid leukemia.An intensive approach to treatment for older patients with relapsed isolated NPM1 mutated AML.Allogeneic transplantation as post-remission therapy for cytogenetically high-risk acute myeloid leukemia: landmark analysis from a single prospective multicenter trial.The role of therapeutic leukapheresis in hyperleukocytotic AML.Prognostic significance of NPM1 mutations in the absence of FLT3-internal tandem duplication in older patients with acute myeloid leukemia: a SWOG and UK National Cancer Research Institute/Medical Research Council report.Cell signaling-based classifier predicts response to induction therapy in elderly patients with acute myeloid leukemia High Doses of Daunorubicin during Induction Therapy of Newly Diagnosed Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis of Prospective Clinical Trials.Similarities and differences between therapy-related and elderly acute myeloid leukemia.The treatment of elderly patients with acute myeloid leukemia.Efficacy of a Mer and Flt3 tyrosine kinase small molecule inhibitor, UNC1666, in acute myeloid leukemia.Older patients with normal karyotype acute myeloid leukemia have a higher rate of genomic changes compared to young patients as determined by SNP array analysis A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy A Phase I Dose Escalation Study of the Triple Angiokinase Inhibitor Nintedanib Combined with Low-Dose Cytarabine in Elderly Patients with Acute Myeloid Leukemia.Development of therapeutic agents for older patients with acute myelogenous leukemia.

P2860

15e224a328263304931e4e66d926275a0aea6926

P248

Q24186270-4BD75551-836B-463B-B0CA-B0800C719CF9 Q24186284-172DDBBA-5DDD-4138-81B7-465C7EC0DF83 Q24187927-93CC3D9F-EB31-41E5-9FC5-B271D8356B93 Q24202630-68C6F78A-C237-4283-84F9-481459FF692B Q24234645-1B2B2861-7D2D-4EFE-8374-DE9E2483182F Q24234680-B680EC92-E968-4FE3-B102-6C55A0A41C3B Q24633763-A1E4DDA0-241A-48D3-A9C8-39415ADB879F Q26772235-9E64FDAA-AD56-4A01-8AF0-4C9901452CBB Q27612411-A01CF0D6-1E82-4756-819F-9B9497A3F9EC Q27684428-0A54CFE5-E969-4EE2-90F7-0BF1757225B9 Q27851545-EEDB337E-9A46-484F-BED2-B23CBA41B3B3 Q30313288-F6D09F46-A219-46E4-B482-64A344DC2844 Q30658847-9EF784E2-E7D9-4637-A50B-734E5412A0BD Q33390055-4F61A49D-E969-4B21-8857-6619E7ECF453 Q33412354-5BE15C72-96DF-4C0E-B4BD-17B9494BA5DA Q33417145-CCB4BADC-6BEA-4DF3-950A-586E2F48BD04 Q33752818-1C8B3C9D-6BD1-4034-B891-92AFCEDFA684 Q33841129-97876D49-7FC5-4D3B-9408-D11638AB01EA Q33985549-E66B1B20-5ED2-4EE2-8B94-47304C3A6D78 Q34167404-B0FE1314-B5FD-4F59-9DB9-DFCC411D0728 Q34202366-1CA23F0D-3CE8-4D7C-AF95-57D28B826864 Q34295164-5CFEFCB8-E131-4DB4-898E-0D13EEF4E473 Q34315531-3D0729FC-3200-4959-9DA2-F70D534F8B49 Q34317679-EAEF7409-8C30-43FE-9FB8-5423C534DC49 Q34451619-0BE6A4A4-C13B-48DD-B138-A549E93881CC Q34541052-08150E84-476B-4A19-9D67-01AD0FA95037 Q34831106-43BA259A-F61A-4305-B9AF-6B63405596D5 Q35082370-F36491EB-2232-4454-9D37-6056CC2C597E Q35082499-5C03068F-C141-4DB8-8945-F41CC85BCDEC Q35148107-7325858A-1276-441D-9B76-0136FA0AAF6E Q35215042-69C0377B-C8B9-4779-9A59-B2DD38032273 Q35462617-C4B66CE9-72A9-4BAC-B285-BE38663A5419 Q35629275-719401F2-51EC-456A-AC0F-F559F3B076D5 Q35640731-E1E4EDF4-7B60-413E-8732-AF93AFDC16FB Q35673578-D6D79830-330D-4B47-944B-4937BB1461B4 Q35740058-61BD436B-9D1F-4238-ABDA-F9A20E8F3A63 Q35783433-7775ABA6-100F-482F-96BB-ED4661D3215F Q35794439-BC40ED2C-D594-407A-9593-8873DBDF14CE Q36157664-1F79B525-AFA1-48B2-A986-D1CAF549912E Q36424315-FFF1D7EC-8204-434E-8389-773444D7BC14

P2860

Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group.

http://www.wikidata.org/entity/Q27851459

description

2009 nî lūn-bûn

@nan

2009 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Age-related risk profile and c ...... id Leukemia Cooperative Group.

@ast

Age-related risk profile and c ...... id Leukemia Cooperative Group.

@en

Age-related risk profile and c ...... id Leukemia Cooperative Group.

@nl

type

label

Age-related risk profile and c ...... id Leukemia Cooperative Group.

@ast

Age-related risk profile and c ...... id Leukemia Cooperative Group.

@en

Age-related risk profile and c ...... id Leukemia Cooperative Group.

@nl

prefLabel

Age-related risk profile and c ...... id Leukemia Cooperative Group.

@ast

Age-related risk profile and c ...... id Leukemia Cooperative Group.

@en

Age-related risk profile and c ...... id Leukemia Cooperative Group.

@nl

P1433

Q27851459-6892BEDE-93DE-44E0-B27E-D65ED0D612E4

P1476

Q27851459-2C295B85-559E-449C-A545-F72298C83525

P2093

Q27851459-0476D649-E94A-4474-A7F2-29AA24DA06C3

Q27851459-14B063EC-6CB6-43EC-8F62-BB76A0AF8F75

Q27851459-174283B3-AE92-4828-BF32-6718769ECB65

Q27851459-3D52DE50-C0F9-48D5-833C-119CEF16FC0F

Q27851459-41C52A7B-FA86-44D5-9439-2976E09B2A06

Q27851459-4EFD1905-8C90-4611-8A4A-26A03D4478F2

Q27851459-5B4FF6BA-3E7E-4773-92C5-D2113BFDCC50

Q27851459-6592E2A0-FCC3-4646-899E-029393BA3F1A

Q27851459-7156D8DA-1C4D-4ED2-A049-A3D0F571E453

Q27851459-745DECFF-2702-4270-AB20-6C23E042642C

P304

Q27851459-0A480E26-8D2B-4AE2-813E-1CD647860091

P31

Q27851459-F9283B23-8B51-49C2-80D9-35B81C65AF88

P3181

Q27851459-355DBAE5-3FE7-4644-B4B0-70B80CE8D8B3

P356

Q27851459-EB243447-16E6-429F-BF84-B07777E65C30

P407

Q27851459-331200AF-0420-4A09-ADE1-19A4B2DCDEBF

P433

Q27851459-4D1F361D-E8B1-4614-94F2-79B064B2561A

P478

Q27851459-3280A5A3-97E1-4D78-93CB-FA68BBB44981

P50

Q27851459-24C7D449-B2AB-4559-86BE-F6E279B30223

Q27851459-2817524F-2AEB-4C3A-AA04-850021C2022A

Q27851459-68A68701-92F2-4366-BC57-BA479132CB5F

Q27851459-8CE86B43-E339-42EB-A085-B4A9D1676459

Q27851459-CDE99445-F55A-41EE-8D5C-28AA49244435

P577

Q27851459-02F5D06B-341A-45F2-9A75-ABF27159C7A5

P5875

Q27851459-F67CBFF5-C77F-4AF2-BD70-B9C0BBE39DC3

P698

Q27851459-5EFEAF60-5110-4632-8BF7-7E74514E9148

P921

Q27851459-3C9B7A80-CDD1-4187-9615-0DB6FFF3C37D

Q27851459-D70BA90B-0C8D-4272-AC09-92C7282813CD

P3181

P356

JCO.2007.15.4245

P1433

Journal of Clinical Oncology

P1476

Age-related risk profile and c ...... id Leukemia Cooperative Group.

@en

P2093

Achim Heinecke

http://www.w3.org/2001/XMLSchema#string

Albrecht Reichle

http://www.w3.org/2001/XMLSchema#string

Andreas Grüneisen

http://www.w3.org/2001/XMLSchema#string

Bernhard Wörmann

http://www.w3.org/2001/XMLSchema#string

Eva Lengfelder

http://www.w3.org/2001/XMLSchema#string

Georg Maschmeyer

http://www.w3.org/2001/XMLSchema#string

Jan Braess

http://www.w3.org/2001/XMLSchema#string

Joachim Kienast

http://www.w3.org/2001/XMLSchema#string

Karsten Spiekermann

http://www.w3.org/2001/XMLSchema#string

Maria-Cristina Sauerland

http://www.w3.org/2001/XMLSchema#string

P304

61-9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

659345

http://www.w3.org/2001/XMLSchema#string

P356

10.1200/JCO.2007.15.4245

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P50

Carsten Müller-Tidow

Torsten Haferlach

Claudia Haferlach

Susanne Schnittger

P577

2009-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23560227

http://www.w3.org/2001/XMLSchema#string

P698

19047294

http://www.w3.org/2001/XMLSchema#string

P921